Atherosclerosis is no longer a disease attributed mainly to the high lipid content of the body but has come to be regarded as a chronic inflammatory disease with an autoimmune component. Atherosclerotic plaques occur preferentially in coronary arteries, where shear stress is oscillatory. Triton WR1339 and atherogenic diet causes decrease in shear stress leading to increased free radical production and endothelial dysfunctioning. It was hypothesized that esmolol increased blood velocity, decreased distal pressure and may cause reversal of abnormal endothelial shear stress, demonstrating a stronger cardioprotective effect, whereas etoricoxib inhibits the COX-2 enzymes thereby inhibits the generation of free radicals during PGs synthesis thus have atheroprotective property. The purpose of this study was to investigate the impact of etoricoxib and esmolol alone and the combination therapy of both. Rats were used for the experiment. All groups were given atherogenic diet and Triton WR-1339 for 60 days and for 7 days respectively. The blood serum was used to estimate the levels of TBARS, Catalase, total cholesterol, triglyceride, LDL and HDL using assay kits. It was concluded that treatment with etoricoxib (10 mg/kg), esmolol (10 mg/kg) and the combination of both drugs have atheroprotective, hypolipidemic, anti-inflammatory, antioxidant effects. This article in a completely novel way focuses on molecular mechanisms involved in the evolution of the atherosclerotic plaque and different novel targets that act at the starting stage of the plaque to the thrombus formation, this may pave the way for selecting optimal therapies and preventing plaque complications.
Loading....